Centre for Commercialization of Regenerative Medicine (CCRM)

The Centre for Commercialization of Regenerative Medicine (CCRM) provides innovative​ contract development and manufacturing organization (CDMO) services to enable the development and commercialization of cell and gene therapies and regenerative medicine-based technologies. With its customer-focused approach customized to each client, CCRM provides process development and current Good Manufacturing Practices (cGMP) manufacturing services tailored to its clients’ timelines, financing, ambitions and needs.


MaRS Centre, West Tower
661 University Avenue – Suite 1002
Toronto, Ontario
M5G 1M1

Areas of Expertise

Good Manufacturing Practices (GMP), induced pluripotent stem cell (iPSC) reprogramming, gene editing, and differentiation

Automated, closed, integrated, process development (PD) and manufacturing for T-cells and natural killer (NK) cells

Viral vector (lentivirus, adeno-associated virus, other) upstream and downstream process development and optimization for manufacturing

GMP-compliant manufacturing of master/working cell banks

Analytical development including high-throughput screening assays, quality control (QC) testing, and ICH stability studies

Assessment of next-generation bioprocessing hardware and technologies


Process R&D
Product R&D
Business Development & Consulting

Contact Information

Website: https://www.ccrm.ca/

Email: cdmo@ccrm.ca

Twitter: @CCRM_ca

LinkedIn: CCRM

Published: September 14, 2021

See how Trillium can help you

Contact Us